Search NEL Online

Clinical Trial 2003; 24(5): 334-338 PubMed PMID: 14647007 Citation  Keywords:  Adenoma:drug therapy, Adult, Antineoplastic Agents:administration & dosage, Apoptosis:drug effects, Female, Humans, Male, Middle Aged, Peptides, Cyclic:administration & dosage, Pituitary Neoplasms:drug therapy, Somatostatin:administration & dosage,.   

OBJECTIVES: Apoptosis of endocrine cells represents one of factors significantly affected the control of hormones secretion. Present study aimed to examine whether treatment of somatotropinoma types tumours with somatostatine analogue (lanreotide) results in apoptosis.

MATERIAL AND METHODS: The studies were performed on 35 patients with somatotropinoma type tumours on whom adenomectomy was performed by transsphenoidal approach. The operative material was examined by cellular morphology, based on light and electron microscopy and chromosomal ladder formation assay.

RESULTS: The number of apoptotic cells showed features typical for the process as condensation and fragmentation of chromatin, vacuolisation, damage of the inner structure of mitochondria and oligonucleosomal fragmentation of DNA was found in the study material. The results of the studies demonstrated the occurrence of lanreotide induced apoptosis in somatotropinoma type tumours. The grade of apoptotic cells in macroadenomas type adenomas, treated with lanreotide, ranged from 4.0% to 17.1% (mean 8.7+/-2.6%). Patients in whom hypophysectomy was not preceded by lanreotide treatment demonstrated low level of apoptotic cells (no more than 3.5%).

CONCLUSIONS: The studies showed that treatment with somatostatine analogue-lanreotide induced apoptosis of tumour cell suggesting that the induction of apoptotic cell death may be involved in the anticancer activity of somatostatine analogue....

Read abstract

Clinical Trial 2002; 23(2): 109-113 PubMed PMID: 12011795 Citation  Keywords:  Adult, Antidepressive Agents, Tricyclic:administration & dosage, Depressive Disorder, Major:drug therapy, Double-Blind Method, Female, Humans, Imipramine:administration & dosage, Inpatients, Male, Middle Aged, Phototherapy, Recurrence, Seasons, Treatment .   

INTRODUCTION: The aim of a double-blind study was to assess the efficacy of bright light therapy and/or imipramine in the treatment of inpatients suffering with recurrent non-seasonal major depressive disorder.

METHOD: 34 in-patients with DSM-III-R diagnosis of major depressive disorder, recurrent type, were randomly allocated into 3 treatment groups. After 4-day washout period with baseline assessment they underwent 3 weeks of different types of treatment: a) Group A: bright light therapy (5000 lux from 6-8 a.m.) and imipramine 150 mg/day. b) Group B: bright light therapy (5000 lux from 6-8 a.m.) and imipramine-like placebo. c) Group C: dim red light (500 lux from 6-8 a.m.) and imipramine 150 mg/day. Outcome measures included weekly Hamilton Psychiatric Rating Scale for Depression, Clinical Global Impression Scale, Montgomery and Asberg Psychiatric Rating Scale for Depression and Beck Depression Inventory.

RESULTS: Patients of all three groups improved significantly. The improvement of the patients of group B treated with bright light therapy plus placebo was superior to the other two groups, but not significantly.

CONCLUSION: Bright light therapy can be effective in the treatment of non-seasonal major depressive disorder....

Read abstract